Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex

Katsumi Sugiyama, Zhou Chen, Yong S. Lee, Peter F. Kador

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A method for the isolation of an intact, non-covalent complex formed by the interaction of aldose reductase, NADP(H) nucleotide, and inhibitor has been developed to aid in the discovery and development of novel aldose reductase inhibitors. In the complexes isolated, both the carboxylic acid-containing inhibitor tolrestat and the spirohydantoin-containing inhibitor AL1576 (2,7-difluorospirofluorene-9,5'-imidazolidine-2',4'-dione) tightly bound in a 1:1 ratio to aldose reductase complexed with either NADPH or NADP+. Inhibitor binding to either the enzyme-NADP+ or enzyme-NADPH complex appeared to be equal and pH-dependent, with maximum binding observed at a pH range of 7 to 8.5 where the inhibitors are ionized. These results indicated that the charge state of the cofactor (NADPH vs NADP+) is not critical for inhibitor binding to aldose reductase. Molecular modeling studies suggested that His110 plays a crucial role in directing charged inhibitors containing either a carboxylate or an ionizable hydantoin group to the active site of aldose reductase by providing charge interaction. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)329-336
Number of pages8
JournalBiochemical Pharmacology
Volume59
Issue number4
DOIs
StatePublished - Feb 15 2000

Fingerprint

Aldehyde Reductase
NADP
Nucleotides
Hydantoins
Molecular modeling
Enzymes
Carboxylic Acids
Catalytic Domain

Keywords

  • Aldose reductase
  • Aldose reductase inhibitors
  • Diabetes
  • Mechanism of action
  • Non-covalent binding

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex. / Sugiyama, Katsumi; Chen, Zhou; Lee, Yong S.; Kador, Peter F.

In: Biochemical Pharmacology, Vol. 59, No. 4, 15.02.2000, p. 329-336.

Research output: Contribution to journalArticle

Sugiyama, Katsumi ; Chen, Zhou ; Lee, Yong S. ; Kador, Peter F. / Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex. In: Biochemical Pharmacology. 2000 ; Vol. 59, No. 4. pp. 329-336.
@article{e743a05b96014418b528cd07f26a232d,
title = "Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex",
abstract = "A method for the isolation of an intact, non-covalent complex formed by the interaction of aldose reductase, NADP(H) nucleotide, and inhibitor has been developed to aid in the discovery and development of novel aldose reductase inhibitors. In the complexes isolated, both the carboxylic acid-containing inhibitor tolrestat and the spirohydantoin-containing inhibitor AL1576 (2,7-difluorospirofluorene-9,5'-imidazolidine-2',4'-dione) tightly bound in a 1:1 ratio to aldose reductase complexed with either NADPH or NADP+. Inhibitor binding to either the enzyme-NADP+ or enzyme-NADPH complex appeared to be equal and pH-dependent, with maximum binding observed at a pH range of 7 to 8.5 where the inhibitors are ionized. These results indicated that the charge state of the cofactor (NADPH vs NADP+) is not critical for inhibitor binding to aldose reductase. Molecular modeling studies suggested that His110 plays a crucial role in directing charged inhibitors containing either a carboxylate or an ionizable hydantoin group to the active site of aldose reductase by providing charge interaction. Copyright (C) 2000 Elsevier Science Inc.",
keywords = "Aldose reductase, Aldose reductase inhibitors, Diabetes, Mechanism of action, Non-covalent binding",
author = "Katsumi Sugiyama and Zhou Chen and Lee, {Yong S.} and Kador, {Peter F.}",
year = "2000",
month = "2",
day = "15",
doi = "10.1016/S0006-2952(99)00332-9",
language = "English (US)",
volume = "59",
pages = "329--336",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex

AU - Sugiyama, Katsumi

AU - Chen, Zhou

AU - Lee, Yong S.

AU - Kador, Peter F.

PY - 2000/2/15

Y1 - 2000/2/15

N2 - A method for the isolation of an intact, non-covalent complex formed by the interaction of aldose reductase, NADP(H) nucleotide, and inhibitor has been developed to aid in the discovery and development of novel aldose reductase inhibitors. In the complexes isolated, both the carboxylic acid-containing inhibitor tolrestat and the spirohydantoin-containing inhibitor AL1576 (2,7-difluorospirofluorene-9,5'-imidazolidine-2',4'-dione) tightly bound in a 1:1 ratio to aldose reductase complexed with either NADPH or NADP+. Inhibitor binding to either the enzyme-NADP+ or enzyme-NADPH complex appeared to be equal and pH-dependent, with maximum binding observed at a pH range of 7 to 8.5 where the inhibitors are ionized. These results indicated that the charge state of the cofactor (NADPH vs NADP+) is not critical for inhibitor binding to aldose reductase. Molecular modeling studies suggested that His110 plays a crucial role in directing charged inhibitors containing either a carboxylate or an ionizable hydantoin group to the active site of aldose reductase by providing charge interaction. Copyright (C) 2000 Elsevier Science Inc.

AB - A method for the isolation of an intact, non-covalent complex formed by the interaction of aldose reductase, NADP(H) nucleotide, and inhibitor has been developed to aid in the discovery and development of novel aldose reductase inhibitors. In the complexes isolated, both the carboxylic acid-containing inhibitor tolrestat and the spirohydantoin-containing inhibitor AL1576 (2,7-difluorospirofluorene-9,5'-imidazolidine-2',4'-dione) tightly bound in a 1:1 ratio to aldose reductase complexed with either NADPH or NADP+. Inhibitor binding to either the enzyme-NADP+ or enzyme-NADPH complex appeared to be equal and pH-dependent, with maximum binding observed at a pH range of 7 to 8.5 where the inhibitors are ionized. These results indicated that the charge state of the cofactor (NADPH vs NADP+) is not critical for inhibitor binding to aldose reductase. Molecular modeling studies suggested that His110 plays a crucial role in directing charged inhibitors containing either a carboxylate or an ionizable hydantoin group to the active site of aldose reductase by providing charge interaction. Copyright (C) 2000 Elsevier Science Inc.

KW - Aldose reductase

KW - Aldose reductase inhibitors

KW - Diabetes

KW - Mechanism of action

KW - Non-covalent binding

UR - http://www.scopus.com/inward/record.url?scp=0033975861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033975861&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(99)00332-9

DO - 10.1016/S0006-2952(99)00332-9

M3 - Article

C2 - 10644040

AN - SCOPUS:0033975861

VL - 59

SP - 329

EP - 336

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 4

ER -